Stay updated with breaking news from Mark Iwicki. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension Completed enrollment in the Phase 2b...
Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial...
KALA BIO, Inc. (NASDAQ:KALA) shares gain ground Friday. The clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial ...
-- Enrolled first patient in CHASE Phase 2b clinical trial evaluating KPI-012 for PCED; Top-line data targeted for 1Q 2024 -- -- Closed $31.0 million... | March 3, 2023
-- On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 ---- Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing,... | November 28, 2022